Podcast: Medera CEO Ronald Li & Keen Vision CEO and Chairman Kenneth Wong
by Kristi Marvin on 2024-12-11 at 9:42am

Innovation in gene therapies is hard, but also potentially ground-breaking and biotechnology firm Medera is taking its decades-long journey in the space to the public markets just as hits its next steps in the clinical process.

This week, we speak with Medera CEO Ronald Li, and Kenneth Wong, CEO and Chairman of Keen Vision Acquisition Corp. The two announced a $622 million dollar combination in September.

Ron explains how Medera has leveraged years of innovations including the capacity to grow miniature human hearts for testing as it advances gene therapies for heart failure that do not rely on animal testing and could prove significantly cheaper than alternatives.

Kenneth tells us why he believes those details align well with the changing regulatory and investment climate around drug development. And, why he views Medera as being a more mature investment play in the biotech space than many of the others coming to market today.

Give it a listen.


spotify-iconApple-podcasts-icon-v2

 

 

 


 

Recent Posts
by Nicholas Alan Clayton on 2025-02-21 at 3:12pm

Part of the fun of the SPAC market is seeing the constantly evolving terms and approaches of teams in both securing their IPOs and their later business combinations. But, there are nonetheless a few hard rules to set the state of play among sponsors and investors, including sacrosanct deadlines for dispersing of trust funds back...

by Nicholas Alan Clayton on 2025-02-21 at 8:25am

At the SPAC of Dawn  Car-sharing networks had their moment in the sun as hot items in the tech scene, with some hopes that the companies could grow to the same scale as vacation rental disrupters like AirBnB (NASDAQ:ABNB). But, signs are showing that this startup category may not be ready for the public markets....

by Nicholas Alan Clayton on 2025-02-20 at 12:54pm

Blue Water III (NASDAQ:BLUWU) has filed for a $200 million SPAC to follow up on the healthcare-focused sponsor’s 2021 pharmaceutical deal. This new SPAC is set to have 1/2 warrants in its units with no overfunding of its trust and a solid 24 months to complete a business combination. It is the third new S-1...

by Nicholas Alan Clayton on 2025-02-20 at 8:22am

At the SPAC of Dawn  While yesterday brought news of better-than expected housing starts, albeit with slightly lower building permits beginning, today’s market news should include an update on jobless claims, which could be a key harbinger of the Fed’s rate cut policy. Other leading economic indicators are set to come in later in the...

by Nicholas Alan Clayton on 2025-02-19 at 4:08pm

CCIS Acquisition Corp (NASDAQ:CCACU) has filed for a $60 million SPAC that would bring a fresh new underwriter to the market in the smaller range of the spectrum. This is the first SPAC IPO filing by underwriter Benjamin Securities Inc. as left lead, although it served as co-manager for Plum IV‘s (NASDAQ:PLMKU) January 15 IPO...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved